Although I am a Canadian medical student who was raised in Vancouver, my parents’ strong roots in Hong Kong and my grandparents’ current residence there have deeply motivated my desire to practice medicine in Hong Kong after my studies. However, I know that my limited connection and familiarity with the medical landscape here would pose a challenge. Thus, I am extremely eager to attend this forum, as I hope to connect with other physicians and gain invaluable insights into Hong Kong’s healthcare system, thus facilitating my transition to practice medicine here in the future.
In addition to clinical networking, I am eager to explore my research interests in emergency medicine and cancer immunotherapy on a global scale. Specifically, my projects involved analyzing risk factors for repeat adverse drug events and investigating metabolic improvements for cellular immunotherapy. As I had only attended conferences within Canada during my master’s degree, I am eager to engage with international experts to exchange ideas and foster cross-cultural collaborations.
Ultimately, this forum presents a unique opportunity for me to bridge my cultural identity with my passion for medicine and scientific research, thus, making my dream of practicing medicine in Hong Kong more of a reality.

Adverse drug events (ADEs) are unintended patient harm caused by the appropriate or inappropriate use of a drug. A repeat ADE is defined as an ADE that has been previously recorded in a patient’s medical record. Repeat ADEs can be caused by exposure to a) the same drug b) a medication within the same drug class or c) an entirely different medication. In addition to causing patient harm, repeat ADEs also pose a significant burden to the Canadian healthcare system, with repeat ADEs accounting for one-third of all ADEs resulting in emergency department presentations in British Columbia.

Certain medication classes and patient factors are associated with an increased risk of ADEs. However, less is known about the medication classes associated with repeat ADEs and the risk factors that predispose patients to repeat ADEs. Thus, our research team will conduct a systematic review to identify the gaps in our medical system that allow for repeat ADEs. By identifying specific medication classes and risk factors that increase the risk of repeat ADEs, we aim to find potential targets for intervention to reduce repeat ADEs and, ultimately, enhance patient care.